TP53 and cancer: For example, tetraploidy was associated with enhanced efficacy of Eg5 inhibitors in cancer models [74], and KIF18A inhibitors were more effective in models with whole genome duplication (WGD), aneuploidy, TP53 mutations, and CIN [142,143,144,145].